Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer
Immune checkpoint inhibitors (ICIs) have recently been approved in subsets of patients with breast cancer (BC). Currently, programmed death ligand 1 (PD-L1) immunohistochemistry is used as a biomarker of response for metastatic triple negative breast cancer (TNBC). Other tumor-agnostic indications i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625005624 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|